Abstract:Abstract Background Ovarian cancer (OC) is the most lethal gynaecological tumor. Changes in glycolysis have been proven to play an important role in OC progression. We aimed to identify a novel glycolysis-related gene signature to better predict the prognosis of patients with OC. Methods mRNA and clinical data were obtained from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and Genotype Tissue Expression (GTEx) database. The “limma” R package was used to identify glycolysis-related differentially expressed genes (DEGs). Then, a multivariate Cox proportional regression model and survival analysis were used to develop a glycolysis-related gene signature. Furthermore, the TCGA training set was divided into two internal test sets for validation, while the ICGC dataset was used as an external test set. A nomogram was constructed in the training set, and the relative proportions of 22 types of tumor-infiltrating immune cells were evaluated using the “CIBERSORT” R package. The enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were determined by single-sample gene set enrichment analysis (ssGSEA) with the “GSVA” R package. Finally, the expression and function of the unreported signature genes ISG20 and SEH1L were explored using immunohistochemistry, western blotting, qRT-PCR, proliferation, migration, invasion and xenograft tumor assays. Results A five-gene signature comprising ANGPTL4, PYGB, ISG20, SEH1L and IRS2 was constructed. This signature could predict prognosis independent of clinical factors. A nomogram incorporating the signature and three clinical features was constructed, and the calibration plot suggested that the nomogram could accurately predict the survival rate. According to ssGSEA, the signature was associated with KEGG pathways related to axon guidance, mTOR signalling, tight junctions, etc. The proportions of tumor-infiltrating immune cells differed significantly between the high-risk group and the low-risk group. The expression levels of ISG20 and SEH1L were lower in tumor tissues than in normal tissues. Overexpression of ISG20 or SEH1L suppressed the proliferation, migration and invasion of Caov3 cells in vitro and the growth of xenograft tumors in vivo. Conclusion Five glycolysis-related genes were identified and incorporated into a novel risk signature that can effectively assess the prognosis and guide the treatment of OC patients.

Development and clinical validation of a seven-gene signature based on tumor stem cell-related genes to predict ovarian cancer prognosis

An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients

Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma

Identification of Prognosis Biomarkers for High-Grade Serous Ovarian Cancer Based on Stemness.

Development of a Five-Gene Signature As a Novel Prognostic Marker in Ovarian Cancer

Identification and validation of a 9-gene signature for the prognosis of ovarian cancer by integrated bioinformatical analysis

Cancer Stem Cell Associated Eight Gene-Based Signature Predicts Clinical Outcomes of Colorectal Cancer

A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer

Development and Verification of a Prognostic Stemness-Related Gene Signature in Triple-Negative Breast Cancer

Construction and Validation of a Novel Glycometabolism-Related Gene Signature Predicting Survival in Patients With Ovarian Cancer

Identification and validation of a novel glycolysis-related gene signature for predicting the prognosis in ovarian cancer

Establishment and validation of a novel invasion-related gene signature for predicting the prognosis of ovarian cancer

Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening.

A stemness-related seven-gene signature for predicting prognosis and treatment response in muscle invasive bladder cancer

Development and Validation of an Immune Gene-Set Based Prognostic Signature in Ovarian Cancer

Integrating Genomic, Epigenomic, and Transcriptomic Features Reveals Modular Signatures Underlying Poor Prognosis in Ovarian Cancer.

Novel Gene Signatures for Prognosis Prediction in Ovarian Cancer.

Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma

Identification and validation of immunity- and disulfidptosis-related genes signature for predicting prognosis in ovarian cancer

Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis

Establishment of a Prognostic Stemness Signature for Cervical Squamous Cell Carcinoma